Literature DB >> 16783851

Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists.

Josef Walker1, David F Tough.   

Abstract

Upon detection of direct and indirect signs of infection, dendritic cells (DC) undergo functional changes that modify their ability to elicit immune responses. Type I interferon (IFN-alpha/beta), which includes a large family of closely related infection-inducible cytokines, represents one indirect signal that can act as a DC stimulus. We have investigated the ability of IFN-alpha/beta subtypes to affect DC function and to influence DC responses to Toll-like receptor (TLR) agonists (i.e., direct infection-associated signals). Subtle differences were observed among 15 subtypes of IFN-alpha/beta in the ability to stimulate expression of maturation markers and chemokines by human monocyte-derived DC, with IFN-omega being the most unique in its effects. Pre-treatment with IFN-alpha/beta did not alter the ability of DC to mature in response to subsequent contact with TLR agonists, but did modulate their secretion of chemokines. Conversely, IFN-alpha/beta was shown to act synergistically with TLR4 but not TLR3 agonists for the induction of maturation and chemokine production when DC were exposed to IFN-alpha/beta and TLR ligands simultaneously. Taken together, these results indicate a complex role for IFN-alpha/beta in regulating DC function during the course an infection, which varies according to IFN-alpha/beta subtype and the timing of exposure to other stimuli.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783851     DOI: 10.1002/eji.200635854

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model.

Authors:  Yifan Ma; Louis Poisson; Guzman Sanchez-Schmitz; Santosh Pawar; Chunfeng Qu; Gwendalyn J Randolph; William L Warren; Eric M Mishkin; Russell G Higbee
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

2.  Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.

Authors:  Shirin Munir; Cyril Le Nouen; Cindy Luongo; Ursula J Buchholz; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

Review 3.  Type I interferons and endoplasmic reticulum stress in health and disease.

Authors:  Jenny Sprooten; Abhishek D Garg
Journal:  Int Rev Cell Mol Biol       Date:  2019-11-19       Impact factor: 6.813

4.  Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.

Authors:  Marisabel Rodriguez Messan; Osman N Yogurtcu; Joseph R McGill; Ujwani Nukala; Zuben E Sauna; Hong Yang
Journal:  PLoS Comput Biol       Date:  2021-09-24       Impact factor: 4.475

5.  Phagocytosis of enterovirus-infected pancreatic beta-cells triggers innate immune responses in human dendritic cells.

Authors:  Barbara M Schulte; Matthijs Kramer; Marleen Ansems; Kjerstin H W Lanke; Neeltje van Doremalen; Jon D Piganelli; Rita Bottino; Massimo Trucco; Jochem M D Galama; Gosse J Adema; Frank J M van Kuppeveld
Journal:  Diabetes       Date:  2010-01-13       Impact factor: 9.461

6.  Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes.

Authors:  Kai Kisand; Maire Link; Anette S B Wolff; Anthony Meager; Liina Tserel; Tõnis Org; Astrid Murumägi; Raivo Uibo; Nick Willcox; Katarina Trebusak Podkrajsek; Tadej Battelino; Anna Lobell; Olle Kämpe; Kari Lima; Antonella Meloni; Berrin Ergun-Longmire; Noel K Maclaren; Jaakko Perheentupa; Kai J E Krohn; Hamish S Scott; Eystein S Husebye; Pärt Peterson
Journal:  Blood       Date:  2008-07-07       Impact factor: 22.113

Review 7.  Interferons at age 50: past, current and future impact on biomedicine.

Authors:  Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.